Home Stock

Stock Research: Esperion Therapeutics

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Esperion Therapeutics

NMQ:ESPR US29664W1053
19
  • Value
    60
  • Growth
    67
  • Safety
    Safety
    42
  • Combined
    16
  • Sentiment
    85
  • 360° View
    360° View
    19
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing oral, non-statin medicines for cardiovascular disease. Its products include NEXLETOL, NEXLIZET, NILEMDO, and NUSTENDI, aimed at lowering elevated LDL-C and cardiovascular risk. In the last fiscal year, the company had 304 employees, a market cap of $228 million, profits of $264 million, and revenue of $332 million.

more
Strongest Rank Dividend Yield
Weakest Rank Pro Holdings
Country USA
Industry Pharmaceuticals
Size Small
Website esperion.com
Index
NASDAQ
Esperion Therapeutics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
60 80 88 55
Growth
67 77 33 7
Safety
Safety
42 37 28 8
Sentiment
85 10 45 1
360° View
360° View
19 47 39 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
15 36 57 9
Opinions Change
63 31 50 37
Pro Holdings
n/a 28 32 53
Market Pulse
80 11 48 20
Sentiment
85 10 45 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
60 80 88 55
Growth
67 77 33 7
Safety Safety
42 37 28 8
Combined
16 84 49 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
100 76 82 38
Price vs. Earnings (P/E)
19 7 100 14
Price vs. Book (P/B)
95 92 100 92
Dividend Yield
1 1 1 1
Value
60 80 88 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
22 43 98 17
Profit Growth
98 86 51 12
Capital Growth
20 98 1 95
Stock Returns
79 29 11 5
Growth
67 77 33 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
4 25 14 1
Refinancing
7 74 73 69
Liquidity
100 24 31 23
Safety Safety
42 37 28 8

Similar Stocks

Discover high‑ranked alternatives to Esperion Therapeutics and broaden your portfolio horizons.

Salesforce

NYQ:CRM
Country: USA
Industry: Application Software
Size: XX-Large
Full Stock Analysis

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

Walt Disney

NYQ:DIS
Country: USA
Industry: Movies & Entertainment
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NSQ:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The only strength is good value. All other factors (growth, safety, and sentiment) are below average. This stock is highly sensitive to a crisis and is not advisable. Avoid unless you have solid, independent reasons to believe a significant turnaround is imminent.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews